Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Estura/pier6, were you also delegates along with Emillykate.......it's just Emillykate's post the other day which was deleted came across as extremely comical :-) I was just wondering as I'm quite confused.
sp drops on no bad news and the panic merchants start to engage with the muppets and a ****ging match prevails blah, blah, blah......ffs if you are a genuine lth sit back and chill......the news you want will be soon :-). by all means say your piece but don't let the muppet brigade get under your skin, this is their moment, let them enjoy it, very soon it will all turn again.
In addition to the excellent safety profile being observed for AVA6000, clear signs of efficacy have now been confirmed. One patient with soft tissue sarcoma has shown a significant reduction in tumour volume in response to the drug, with further signs of activity observed in patients with cancers not limited to soft tissue sarcoma.
In light of the positive data emerging from the ALS-6000-101 study the Company has adapted its clinical development strategy with the aim of bringing forward the start of a potentially pivotal phase 2 study in soft tissue sarcoma, subject to receiving the necessary regulatory approvals.
The excellent safety profile of AVA6000 should allow more frequent and/or higher dosing compared with the standard doxorubicin regimen which could in turn improve the outcome for patients. Therefore, in parallel with the completion of cohort 7, the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a first line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA).
The study is designed to determine whether fortnightly or three weekly dosing should be the recommended Phase 2 dosing regimen, as well as potentially providing additional indications of activity in soft tissue sarcoma patients. The study will replace the much longer planned Phase 1b efficacy study, and is expected to allow the Company to bring forward the start of the potentially pivotal Phase 2 efficacy study into 2024.
The Company expects to publish detailed data from the ALS-6000-101 clinical study, including clinical and pharmacokinetic data, in the fourth quarter of 2023.
Speaks for itself :-)
Dr Tap this morning officially told the FDA this is the bees knees :-) word is J&J $40B offer has been rejected by AVCT board :-) But DYOR......as these BB's can sometimes provide inaccurate info :-)
Sheppy, when did AS tell you it was going to be massive, that is brilliant news.
When I was a lad
And old Shep was a pup
Over hills and meadows we'd stray
Just a boy and his dog
We were both full of fun
We grew up together that way
I remember the time at the old swimmin' hole .........................
"and you could see in yesterday's presentation there were moments when he was literally holding back from saying something not yet public knowledge"
Absolutely Nanomat, his words IMO were extremely rampy and I couldn't help notice he repeated himself on several occasions in order to re-emphasise his message. For a company that supposedly doesn't boost I got the distinct impression that is about to change :-)
Thanks for that invaluable info LTI, very appreciated.....you're an experienced investor who perhaps takes things rather too seriously. To coin your own phrase, maybe you should follow the "pinch of salt" analogy 😊. Good luck with your investments.
LTI "Saga is not one of my top investments so I do not peruse on a daily basis"............Really :-)
Maybe you need to take the posts on here a little less serious, take a chill pill and peruse a little less often :-)
BTW you answered your own "research" query to Aspers when you clearly state the following " Does anyone think that any research was necessary after a big fall in price in 4 weeks without any news to back up the fall, to then not expect a bounce"
Perhaps that was the only research Aspers required and didn't need to share the obvious.
I don't want an argument LTI, I just pointed out you were giving Aspers a hard time for perhaps personal gain.
Feel free to use/like this comment to acknowledge that Billzo & Buglet11 are the same person :-) and their sub £1 prediction didn't happen.....at least today, works both ways Billzo :-)
LTI, you seem to be picking on Aspers for suggesting 130p yet you haven't called out the chuckle brothers for suggesting sub £1. Seems a bit one sided / biased, after all, the posts are just tongue and cheek and if you genuinely think people are influenced by other posts on here......well, enough said !!!